(Q38376336)

English

Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial

scientific article published on 22 May 2017

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

2 September 2017

Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial (English)

1 reference

Europe PubMed Central

2 September 2017

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

Robert M. Grant

object named as

Robert M Grant

3

0 references

Magdalena E. Sobieszczyk

8

object named as

Magdalena E Sobieszczyk

1 reference

Europe PubMed Central

2 September 2017

4

object named as

Kenneth H Mayer

1 reference

Europe PubMed Central

2 September 2017

author name string

Martin Markowitz

1

1 reference

Europe PubMed Central

2 September 2017

Ian Frank

2

1 reference

Europe PubMed Central

2 September 2017

Richard Elion

5

1 reference

Europe PubMed Central

2 September 2017

Deborah Goldstein

6

1 reference

Europe PubMed Central

2 September 2017

Chester Fisher

7

1 reference

Europe PubMed Central

2 September 2017

Joel E Gallant

9

1 reference

Europe PubMed Central

2 September 2017

Hong Van Tieu

10

1 reference

Europe PubMed Central

2 September 2017

Winkler Weinberg

11

1 reference

Europe PubMed Central

2 September 2017

David A Margolis

12

1 reference

Europe PubMed Central

2 September 2017

Krischan J Hudson

13

1 reference

Europe PubMed Central

2 September 2017

Britt S Stancil

14

1 reference

Europe PubMed Central

2 September 2017

Susan L Ford

15

1 reference

Europe PubMed Central

2 September 2017

Parul Patel

16

1 reference

Europe PubMed Central

2 September 2017

Elizabeth Gould

17

1 reference

Europe PubMed Central

2 September 2017

Alex R Rinehart

18

1 reference

Europe PubMed Central

2 September 2017

Kimberly Y Smith

19

1 reference

Europe PubMed Central

2 September 2017

William R Spreen

20

1 reference

Europe PubMed Central

2 September 2017

publication date

22 May 2017

1 reference

Europe PubMed Central

2 September 2017

The lancet. HIV

1 reference

Europe PubMed Central

2 September 2017

4

1 reference

Europe PubMed Central

2 September 2017

8

1 reference

Europe PubMed Central

2 September 2017

e331-e340

1 reference

Europe PubMed Central

2 September 2017

Bone mineral density decline according to renal tubular dysfunction and phosphaturia in tenofovir-exposed HIV-infected patients.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2817%2930068-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2817%2930068-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Drug resistance and plasma viral RNA level after ineffective use of oral pre-exposure prophylaxis in women

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2817%2930068-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Liver and renal safety of tenofovir disoproxil fumarate in combination with emtricitabine among African women in a pre-exposure prophylaxis trial

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2817%2930068-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Preexposure prophylaxis for HIV infection among African women

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2817%2930068-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-acting injectable antiretrovirals for HIV treatment and prevention

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2817%2930068-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics, safety, and tolerability with repeat doses of GSK1265744 and rilpivirine (TMC278) long-acting nanosuspensions in healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2817%2930068-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2817%2930068-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2817%2930068-1

7 January 2021

based on heuristic

inferred from DOI database lookup

GSK1265744 pharmacokinetics in plasma and tissue after single-dose long-acting injectable administration in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2817%2930068-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2817%2930068-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2817%2930068-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2817%2930068-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2817%2930068-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2817%2930068-1

7 January 2021

based on heuristic

inferred from DOI database lookup

On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2817%2930068-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2817%2930068-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S2352-3018(17)30068-1

1 reference

Europe PubMed Central

2 September 2017

1 reference

Europe PubMed Central

2 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38376336&oldid=1756622205"